Nephrocare Health Services Ltd. IPO
Nephrocare Health Services Ltd. is India’s and Asia’s largest dialysis services provider, offering comprehensive dialysis care through a wide clinic network. The company provides end-to-end renal care—including haemodialysis, home dialysis, mobile dialysis, and wellness support—making it the largest player in India across patients served, treatments performed, clinics, cities covered, revenue and EBITDA (FY 2025).
Business Model
Nephrocare operates an asset-light and capital-efficient model, with:
i) 52.41% of clinics under revenue-sharing arrangements, requiring minimal upfront capex.
ii) Rapid breakeven for brownfield and captive clinics—typically 3–4 months.
iii) Greenfield clinics breakeven in 12 months.
The mixed model of greenfield, brownfield, hospital partnerships, and PPPs has enabled rapid nationwide and international expansion
Scale & Market Leadership
Nephrocare is India’s largest dialysis services provider—4.4× bigger than the next organized player by operating revenue—and also the largest in Asia and 5th largest globally based on treatments performed in FY 2025. In FY 2025, the company served 29,281 patients and delivered 28.85 lakh treatments, accounting for nearly 10% of India’s dialysis patients. As of September 30, 2025, Nephrocare had already served 31,046 patients with 15.91 lakh treatments.
Extensive Clinic Network
Nephrocare operates:
– 519 clinics globally, including 51 international clinics across Philippines (41), Nepal (6), Uzbekistan (4).
– Most widely distributed network in India with presence across 288 cities, 21 states, and 4 union territories.
– 77.35% clinics located in Tier II & Tier III cities, reinforcing accessibility in underserved regions.
Service Philosophy: Accessibility, Quality & Value
Nephrocare’s service philosophy centers on Accessibility, Quality, and Value. It ensures wide access through a pan-India network of in-hospital clinics, standalone centers, PPP units, and services like holiday dialysis and dialysis-on-wheels. Quality is maintained through standardized, protocol-driven care using its proprietary RenAssure® Protocols. Its asset-light, scalable model enables cost-efficient operations and rapid expansion while delivering high-value dialysis care.
Objects of the Nephrocare Health Services Ltd. IPO:
Nephrocare Health Services Ltd. IPO Details:
| Open Date: | Dec 10 2025 |
| Close Date: | Dec 12 2025 |
| Total Shares: | 1,89,35,819 |
| Face Value: | ₹ 2 Per Equity Share |
| Issue Type: | Book Building |
| Issue Size: | 871.05 Cr. |
| Lot Size: | 32 Shares |
| Issue Price: | ₹ 438 - 460 Per Equity Share |
| Listing At: | NSE,BSE |
| Listing Date: | Dec 17 2025 |
Promoters And Management:
Financials of Nephrocare Health Services Ltd. IPO:
| Particulars | 6M FY2025-26 | FY 2024-25 | FY 2023-2024 | FY 2022-2023 |
| Revenue from Operations (Cr) | 473.50 | 755.80 | 566.10 | 437.20 |
| EBITDA (Cr) | 110.30 | 166.60 | 99.60 | 48.50 |
| EBITDA Margins | 23.30% | 22.05% | 17.60% | 11.11% |
| PAT (Cr) | 14.2 | 67 | 35 | -11.7 |
| PAT Margins | 3.00% | 8.88% | 6.21% | -2.70% |
| ROCE | 11.99% | 18.68% | 10.00% | 0.44% |
| D/E Ratio | 0.28 | 0.37 | 0.57 | 0.51 |
| OPerating Cash Flow | 38.1 | 135.3 | 72.2 | 11.2 |
Comparison With Peers:
| Companies | Revenue (in cr) | EBITDA Margins | PAT Margins | ROCE | D/E Ratio | MCap (in cr) | P/E |
| Nephrocare Health Services Limited | 755.80 | 22.05% | 8.88% | 18.68% | 0.37 | Updated Soon | Updated Soon |
| Jupiter Life Line Hospitals | 1262 | 24% | 15.37% | 18.00% | 0.28 | 9485 | 48 |
| Rainbow Children Hospital | 1516 | 33% | 16.09% | 18.70% | 0.54 | 13688 | 53.9 |
| Dr. Agarwal’s Healthcare | 1711 | 27% | 6.4 | 9.90% | 0.51 | 16128 | 139 |
| Dr. Lal Path Labs | 2461 | 28% | 19.90% | 28.99% | 0.07 | 25211 | 47 |
| Metropolis Healthcare | 1331 | 23% | 10.96% | 14.70% | 0.14 | 10018 | 63.3 |
| Vijaya Diagnostics | 681 | 40% | 19.90% | 20.90% | 0.42 | 10216 | 67 |
Lead Manager of Nephrocare Health Services Ltd. IPO:
Registrar of Nephrocare Health Services Ltd. IPO:
Discussion on Nephrocare Health Services Ltd. IPO:
Leave a Reply
You must be logged in to post a comment.